Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Phibro Animal Health (PAHC) Shares Outstanding (Weighted Average) (2016 - 2026)

Phibro Animal Health has reported Shares Outstanding (Weighted Average) over the past 13 years, most recently at $40.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed 0.07% year-over-year to $40.5 million; the TTM value through Dec 2025 reached $40.5 million, changed 0.07%, while the annual FY2025 figure was $40.5 million, 0.03% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $40.5 million at Phibro Animal Health, roughly flat from $40.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $40.5 million in Q3 2025 and troughed at $40.5 million in Q2 2021.
  • A 5-year average of $40.5 million and a median of $40.5 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 0.12% in 2021 and later changed 0.0% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $40.5 million in 2021, then changed by 0.0% to $40.5 million in 2022, then changed by 0.0% to $40.5 million in 2023, then changed by 0.0% to $40.5 million in 2024, then increased by 0.07% to $40.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PAHC at $40.5 million in Q4 2025, $40.5 million in Q3 2025, and $40.5 million in Q2 2025.